CO6251359A2 - Compuestos de indolobenzazepina sustituida por heteroarilo - Google Patents

Compuestos de indolobenzazepina sustituida por heteroarilo

Info

Publication number
CO6251359A2
CO6251359A2 CO10011252A CO10011252A CO6251359A2 CO 6251359 A2 CO6251359 A2 CO 6251359A2 CO 10011252 A CO10011252 A CO 10011252A CO 10011252 A CO10011252 A CO 10011252A CO 6251359 A2 CO6251359 A2 CO 6251359A2
Authority
CO
Colombia
Prior art keywords
alkyl
hydrogen
dialkylamino
alkylamino
cycloalkyl
Prior art date
Application number
CO10011252A
Other languages
English (en)
Spanish (es)
Inventor
Scott W Martin
Carl P Bergstrom
Kap-Sun Yeung
Robert G Gentles
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO6251359A2 publication Critical patent/CO6251359A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO10011252A 2007-08-09 2010-02-03 Compuestos de indolobenzazepina sustituida por heteroarilo CO6251359A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US4994408P 2008-05-02 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C

Publications (1)

Publication Number Publication Date
CO6251359A2 true CO6251359A2 (es) 2011-02-21

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10011252A CO6251359A2 (es) 2007-08-09 2010-02-03 Compuestos de indolobenzazepina sustituida por heteroarilo

Country Status (18)

Country Link
US (1) US7652004B2 (enExample)
EP (1) EP2183252B1 (enExample)
JP (1) JP5465670B2 (enExample)
KR (1) KR20100066492A (enExample)
CN (1) CN101821267B (enExample)
AR (1) AR067897A1 (enExample)
AU (1) AU2008293845B2 (enExample)
BR (1) BRPI0814931A2 (enExample)
CA (1) CA2695781A1 (enExample)
CL (1) CL2008002353A1 (enExample)
CO (1) CO6251359A2 (enExample)
EA (1) EA015978B1 (enExample)
MX (1) MX2010001416A (enExample)
NZ (1) NZ583149A (enExample)
PE (1) PE20090618A1 (enExample)
TW (1) TW200906418A (enExample)
WO (1) WO2009029384A2 (enExample)
ZA (1) ZA201000923B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 5−5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5416710B2 (ja) * 2007-11-20 2014-02-12 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンズアゼピンhcvns5b阻害剤
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
AU2009228451A1 (en) 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102388045A (zh) * 2009-02-11 2012-03-21 百时美施贵宝公司 用于治疗丙型肝炎的化合物
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド C型肝炎阻害剤およびその使用
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
DE112012002522T5 (de) 2011-06-22 2014-03-13 Central Glass Co., Ltd. Verfahren zur Herstellung einer Pyrazol-Verbindung
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585084A1 (en) 2004-10-26 2006-05-04 Immacolata Conte Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
AR067897A1 (es) 2009-10-28
MX2010001416A (es) 2010-03-01
NZ583149A (en) 2011-07-29
EA201000277A1 (ru) 2010-06-30
AU2008293845A1 (en) 2009-03-05
CL2008002353A1 (es) 2008-10-24
AU2008293845B2 (en) 2013-02-14
EP2183252B1 (en) 2015-01-14
TW200906418A (en) 2009-02-16
WO2009029384A2 (en) 2009-03-05
EP2183252A2 (en) 2010-05-12
EA015978B1 (ru) 2012-01-30
US7652004B2 (en) 2010-01-26
KR20100066492A (ko) 2010-06-17
PE20090618A1 (es) 2009-05-16
CN101821267B (zh) 2013-07-10
WO2009029384A3 (en) 2009-05-28
CA2695781A1 (en) 2009-03-05
ZA201000923B (en) 2011-04-28
US20090074715A1 (en) 2009-03-19
CN101821267A (zh) 2010-09-01
JP5465670B2 (ja) 2014-04-09
BRPI0814931A2 (pt) 2015-02-03
JP2010535787A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
CO6251359A2 (es) Compuestos de indolobenzazepina sustituida por heteroarilo
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
AR061053A1 (es) Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR055165A1 (es) Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c.
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
PH12012500487A1 (en) Herbicidal pyrimidone derivatives
AR071684A1 (es) Compuestos para el tratamiento de la hepatitis c
JP2010521483A5 (enExample)
CO2017003132A2 (es) Inhibidores de la aldosterona sintasa derivados de la 2,6-diazaspiro[3.3]heptán-6-il]-3-piridil]isoindolín-1-ona o 2,7-diazaspiro[3.5]nonán-2-il]-3-piridil]isoindolín-1-ona
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
AR065276A1 (es) Herbicidas de n-oxidos de piridina sustituidos
NO20091704L (no) Inhibitorer av hepatitt C virus
NO20091707L (no) Inhibitorer av hepatitt C virus
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
RU2011131048A (ru) Новое бициклическое гетероциклическое соединение
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
ECSP088253A (es) Derivados de azol y tiazol y sus usos
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
IN2012DN00869A (enExample)
PE20081409A1 (es) Antagonistas del receptor de progesterona
AR057872A1 (es) Inhibidores de la proteina activadora de 5-lipoxigenasa (flap)
EA201100368A1 (ru) Амидные соединения, полезные в терапии

Legal Events

Date Code Title Description
FC Application refused